TCH方案在Her-2阳性乳腺癌新辅助治疗的临床疗效观察

目的探讨TCH(多西他赛+卡铂+曲妥珠单抗)方案在Her-2阳性乳腺癌新辅助治疗中的临床疗效。方法对21例Her-2阳性乳腺癌(ⅡB期～ⅢC期)术前行TCH方案的新辅助治疗4～6个周期,评价临床疗效,并中位随访2年观察无病生存率及总生存率。结果 21例患者中CR 16例(76.19%),其中达到PCR 13例(61.90%),PR 3例(14.29%),SD 2例(9.52%)。总有效率(CR+PR)达:90.48%,2年的无病生存率为95.23%,总生存率为100%。结论应用TCH方案行新辅助治疗可有效提高Her-2阳性乳腺癌患者的临床缓解率,使一部分患者获得保乳手术的机会,提高手术成功率,并改善患者的生存率。

Clinical Efficacy Observations of Neoadjuvant Therapy with TCH Regimen in Treatment of Her-2-overexpressing Breast Cancer

Objective To observe the clinical efficacy of neoadjuvant therapy with TCH regimen(Trastuzumb combined with docetaxel and carbopatin) in treatment of Her-2-overexpressing breast cancer.Methods Twenty one patients with Her-2(+++)breast cancer(clinical stage ⅡB-ⅢC)received neoadjuvant therapy with TCH regimen 4-6 cycles before operation.Clinical effect and disease-free survival rate(DFS)and overall survival rate(OS) were observed and compared during mean 2 years follow-up.Results Among 21 patients after neoadjuvant therapy,16 cases were complete remission(CR)(76.19%),13 case had pathological complete response(PCR)(61.90%),3 cases were partial remission(PR)(14.29%),and 2 cases were steady(SD)(9.52%).Total clinical response rate(CR+PR) was 90.48%.DFS of two years was 95.23%,and OS of two years was 100%.Conclusion Neoadjuvant therapy using TCH regimen can improve clinical remission rate and survival rate in Her-2-overexpressing breast cancer,and can obtain chance of breast-conserving surgery therapy and increase achievement ratio of surgery.